Key chemokines and their receptors included B2M, CCL17, CCL22, CCL3, CCL4, CCL5, CCR2, CCR4, CCR5, CXCL1, and CXCL16, CXCR3, CXCR6, and XCL2 were also significantly upregulated in the low-risk group (Figure 7B), suggesting that additional anti-tumor immune cells might be recruited in low-risk patients. Here, CXCL16 is linked to neoplasm.